CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial – Markets Insider
|
CARsgen Launches First-in-Class Anti-Claudin18.2 CAR–T Clinical Trial
Markets Insider SHANGHAI, Aug. 10, 2017 /PRNewswire/ — CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR–T cell) therapies for solid tumors, today announced its first-in-class anti-Claudin18.2-CAR–T cell therapy for … |
